Publications by authors named "B Mayrbaeurl"
Article Synopsis
- Cancer treatments can negatively impact physical health and quality of life, with exercise emerging as a potential remedy that requires more research.
- The ABCSG C07-EXERCISE study looked at a year-long exercise program for colorectal cancer patients post-chemotherapy and tracked their quality of life using standardized questionnaires.
- Results showed significant improvements in social functioning and moderate gains in other areas like pain and financial impact, suggesting structured exercise could enhance quality of life for cancer survivors, but more extensive studies are needed to confirm these findings.
Primary CNS lymphoma is a highly aggressive and rare type of extranodal non-Hodgkin lymphoma. Although, new therapeutic approaches have led to improved survival, the management of the disease poses a challenge, practice patterns vary across institutions and countries, and remain ill-defined for vulnerable patient subgroups. Using information from the Austrian Brain Tumor Registry we followed a population-based cohort of 189 patients newly diagnosed from 2005 to 2010 through various lines of treatment until death or last follow-up (12-31-2016).
View Article and Find Full Text PDFHereditary diffuse gastric cancer (HDGC) is an autosomal-dominantly inherited cancer syndrome associated with a high risk for diffuse gastric and lobular breast cancer, caused by heterozygous CDH1 germline mutations. Of note, also cleft lip/palate (CLP) has been described in few HDGC families. Here we report on an extensive pedigree presenting with HDGC, CLP and a CDH1 splice site mutation (c.
View Article and Find Full Text PDFThe term refeeding syndrome (RFS) refers to the metabolic perturbations and its attendant complications in subjects who are refed after fasting. The syndrome is characterized by profound shifts of electrolytes and fluids. Its consequences are widespread and sometimes fatal.
View Article and Find Full Text PDFArticle Synopsis
- Chronic myelomonocytic leukemia (CMML) was previously classified under myelodysplastic syndromes (MDS), and treatment data is mainly derived from MDS trials.
- A phase I trial was conducted using lenalidomide on 20 CMML patients to determine the maximum tolerated dose (MTD) and assess safety and response.
- The MTD was found to be 5 mg daily, with some patients showing partial remission or stable disease, but further research is needed to confirm the drug's efficacy, as the main toxicity noted was thrombocytopenia.